Study shows first extensive and stable microbiome remodeling via B. infantis in infants

December 06, 2017

Evolve BioSystems, Inc. today announced positive results from their landmark clinical trial in support of Evivo™, an activated form of the beneficial bacteria Bifidobacterium longum subsp. infantis (B. infantis EVC001, ActiBif®). The study showed that providing dietary B. infantis EVC001 resulted in rapid, substantial, and persistent remodeling of the gut microbiome in breastfed infants. This stable colonization of B. infantis EVC001 led to significant reduction in the abundance of potentially harmful bacteria. In addition, this improved gut profile persisted for more than 30 days after dietary B. infantis was discontinued, as long as infants continued to consume breast milk. The findings from the IMPRINT (Infant Microbiome Probiotic Intake Trial) clinical trial were published this week in the American Society for Microbiology journal mSphere.

Historically, bifidobacteria, particularly B. infantis, created a protective microbial environment by dominating the infant gut, and continue to do so today in many developing countries. However, modern medical practices such as antibiotic use and C-section deliveries have led to the near-total loss of this keystone gut microbe in infants in developed countries, creating widespread gut dysbiosis. A dysbiotic gut microbiome during infancy has been associated with the growing pandemic of chronic health issues including allergies, asthma, obesity, and type 1 diabetes. To date, no other clinical study has demonstrated a substantial change in the gut microbiome via probiotic use.

"These results with B. infantis EVC001 demonstrate for the first time that when the appropriate probiotic bacteria is provided in combination with breast milk, it can rapidly and stably colonize the infant gut microbiome while significantly reducing levels of potentially harmful bacteria linked to long-term disease," said Mark Underwood M.A.S., M.D., Chief of Pediatric Neonatology and Professor of Pediatrics at the University of California Davis and a principle investigator on the study. "This study is extremely important for infant health and nutrition because we may now have the potential to impact many common health issues by simply restoring the microbiome to its natural state."

The IMPRINT study showed that breastfed infants who received the probiotic achieved a 79% increase in levels of Bifidobacteria, as measured in stool samples and subsequently confirmed to be B. infantis EVC001. Additionally, these infants experienced an 80% reduction of potentially harmful bacteria like Clostridium and E. coli, which have been linked to chronic diseases later in life. The study also demonstrated that infants colonized at high levels by bifidobacteria, including B. infantis EVC001, had significantly lower levels of endotoxin, a known trigger of inflammation. The IMPRINT results further confirmed the unique mechanism of action of B. infantis EVC001, showing it maintained its dominant position in the infant microbiome as a result of its unique ability to consume certain components of human milk (human milk oligosaccharides; HMOs) that are otherwise unused by the infant.

"The IMPRINT results confirm that B. infantis is a uniquely-adapted bacterial partner to human breast milk, and its presence in the infant gut at high levels demonstrates restoration of the original, natural state of the infant microbiome," said David Kyle, Ph.D., Chairman of the Board and Chief Scientific Officer at Evolve BioSystems.

"This pivotal trial demonstrates a major advancement in the rapidly expanding field of microbiome research and, for the first time, identifies an immediate practical application that could have an impact on the health of infants worldwide," said Timothy Brown, CEO at Evolve BioSystems. "This exciting research supports Evivo as an important means of restoring and maintaining a healthy newborn gut microbiome."
-end-
About the IMPRINT trial

The IMPRINT trial was a parallel, controlled clinical study in exclusively breastfed infants, that included 68 mother-infant pairs who received either lactation support plus B. infantis EVC001 or lactation support alone. Infants randomized to the probiotic group received one daily serving of B. infantis EVC001 for 21 consecutive days starting on day seven after birth and continued through day 27. The study design, as well as safety and tolerability results were previously published by Smilowitz et al in BMC Pediatrics (2017).

About Evolve BioSystems

Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the development and commercial launch of products to resolve newborn gut dysbiosis, including Evivo? for infants and GlycoGuard? for nursing foals, Evolve's discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle as well as other animal species. In addition to the landmark proof-of-concept IMPRINT trial, Evolve is undertaking further clinical studies to build out its suite of microbiome-based solutions.

For more information please visit http://www.evolvebiosystems.com.

Weber Shandwick

Related Microbiome Articles from Brightsurf:

Managing the microbiome raises new hope for autism
Analysis of 619 plasma metabolites in a new study show a distinctive metabolic profile in autistic children prior to microbial transfer therapy The procedure helps modify gut microbiota, improving symptoms gastrointestinal and behavioral symptoms of the disease.

Discoveries reshape understanding of gut microbiome
The findings redefine how the so-called gut microbiome operates and how our bodies coexist with some of the 100 trillion bacteria that make it up.

A new tool for modeling the human gut microbiome
MIT engineers designed a device that replicates the lining of the colon.

How viruses and bacteria balance each other in the gut microbiome
A tiny arms race between bacteria and the viruses that attack them inside the gut could eventually offer a new way to treat out-of-balance microbiomes.

Microbiome confers resistance to cholera
Many parts of the world are in the midst of a deadly pandemic of cholera, an extreme form of watery diarrhea.

Parasites and the microbiome
In a study of ethnically diverse people from Cameroon, the presence of a parasite infection was closely linked to the make-up of the gastrointestinal microbiome, according to a research team led by Penn scientists.

Gut microbiome influences ALS outcomes
Harvard University scientists have identified a new gut-brain connection in the neurodegenerative disease ALS.

The microbiome controls immune system fitness
Working alongside colleagues in Mainz, Bern, Hannover and Bonn, researchers from Charité -- Universitätsmedizin Berlin, the Berlin Institute of Health (BIH) and the German Rheumatism Research Center Berlin (DRFZ) were able to show how the microbiome helps to render the immune system capable of responding to pathogens.

Researchers uncover the moscow subway microbiome
Recently, a group of ITMO University researchers has looked into the microbiome of the Moscow Subway.

Study provides first look at sperm microbiome using RNA sequencing
A new collaborative study published by a research team from the Wayne State University School of Medicine, the CReATe Fertility Centre and the University of Massachusetts Amherst provides the first in-depth look at the microbiome of human sperm utilizing RNA sequencing with sufficient sensitivity to identify contamination and pathogenic bacterial colonization.

Read More: Microbiome News and Microbiome Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.